Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism

Kyoung Jin Oh, Jinyoung Park, Su Yeon Lee, Injae Hwang, Jae Bum Kim, Tae Sik Park, Heon-Jeong Lee, Seung-Hoi Koo

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Dysregulation of lipid metabolism is a key feature of metabolic disorder related to side effects of antipsychotic drugs. Here, we investigated the molecular mechanism by which second-generation atypical antipsychotic drugs (AAPDs) affect hepatic lipid metabolism in liver. AAPDs augmented hepatic lipid accumulation by activating expression of sterol regulatory element-binding protein (SREBP) transcription factors, with subsequent induction of downstream target genes involved in lipid and cholesterol synthesis in hepatocytes. We confirmed the direct involvement of SREBPs on AAPD-induced expression of lipogenic and cholesterogenic genes by utilization of adenovirus for dominant negative SREBP (Ad-SREBP-DN). Interestingly, AAPDs significantly decreased phosphorylation of AMPKα and expression of fatty acid oxidation genes. Treatment of constitutive active AMPK restored AAPD-mediated dysregulation of genes involved in both lipid synthesis and fatty acid oxidation. Moreover, AAPDs decreased transcriptional activity of PPARα, a critical transcriptional regulator for controlling hepatic fatty acid oxidation, via an AMPKdependent manner. Close investigations revealed that mutations at the known p38 MAPK phosphorylation sites (S6/12/21A), but not mutations at the putative AMPKα phosphorylation sites (S167/373/453A), block AAPD-dependent reduction of PPARα transcriptional activity, suggesting that p38 MAPK might be also involved in the regulatory pathway as a downstream effector of AAPDs/AMPK. Taken together, these data suggest that AAPD-stimulated hepatic dysregulation of lipid metabolism could result from the inhibition of AMPK activity, and pharmaceutical means to potentiate AMPK activity would contribute to restore hepatic lipid homeostasis that occurs during AAPD treatment.

Original languageEnglish
Pages (from-to)624-632
Number of pages9
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume300
Issue number4
DOIs
Publication statusPublished - 2011 Apr 1

Fingerprint

AMP-Activated Protein Kinases
Lipid Metabolism
Antipsychotic Agents
Liver
Sterol Regulatory Element Binding Proteins
Lipids
Peroxisome Proliferator-Activated Receptors
Fatty Acids
Phosphorylation
p38 Mitogen-Activated Protein Kinases
Genes
S 6
Mutation
Drug-Related Side Effects and Adverse Reactions
Adenoviridae
Hepatocytes
Homeostasis
Transcription Factors
Cholesterol

Keywords

  • Adenosine 5'-monophosphate-activated protein kinase
  • Peroxisome proliferator-activated receptor-α
  • Sterol regulatory element-binding protein

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Endocrinology, Diabetes and Metabolism

Cite this

Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism. / Oh, Kyoung Jin; Park, Jinyoung; Lee, Su Yeon; Hwang, Injae; Kim, Jae Bum; Park, Tae Sik; Lee, Heon-Jeong; Koo, Seung-Hoi.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 300, No. 4, 01.04.2011, p. 624-632.

Research output: Contribution to journalArticle

Oh, Kyoung Jin ; Park, Jinyoung ; Lee, Su Yeon ; Hwang, Injae ; Kim, Jae Bum ; Park, Tae Sik ; Lee, Heon-Jeong ; Koo, Seung-Hoi. / Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism. In: American Journal of Physiology - Endocrinology and Metabolism. 2011 ; Vol. 300, No. 4. pp. 624-632.
@article{01af4ce85da1442799432b61755e7b14,
title = "Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism",
abstract = "Dysregulation of lipid metabolism is a key feature of metabolic disorder related to side effects of antipsychotic drugs. Here, we investigated the molecular mechanism by which second-generation atypical antipsychotic drugs (AAPDs) affect hepatic lipid metabolism in liver. AAPDs augmented hepatic lipid accumulation by activating expression of sterol regulatory element-binding protein (SREBP) transcription factors, with subsequent induction of downstream target genes involved in lipid and cholesterol synthesis in hepatocytes. We confirmed the direct involvement of SREBPs on AAPD-induced expression of lipogenic and cholesterogenic genes by utilization of adenovirus for dominant negative SREBP (Ad-SREBP-DN). Interestingly, AAPDs significantly decreased phosphorylation of AMPKα and expression of fatty acid oxidation genes. Treatment of constitutive active AMPK restored AAPD-mediated dysregulation of genes involved in both lipid synthesis and fatty acid oxidation. Moreover, AAPDs decreased transcriptional activity of PPARα, a critical transcriptional regulator for controlling hepatic fatty acid oxidation, via an AMPKdependent manner. Close investigations revealed that mutations at the known p38 MAPK phosphorylation sites (S6/12/21A), but not mutations at the putative AMPKα phosphorylation sites (S167/373/453A), block AAPD-dependent reduction of PPARα transcriptional activity, suggesting that p38 MAPK might be also involved in the regulatory pathway as a downstream effector of AAPDs/AMPK. Taken together, these data suggest that AAPD-stimulated hepatic dysregulation of lipid metabolism could result from the inhibition of AMPK activity, and pharmaceutical means to potentiate AMPK activity would contribute to restore hepatic lipid homeostasis that occurs during AAPD treatment.",
keywords = "Adenosine 5'-monophosphate-activated protein kinase, Peroxisome proliferator-activated receptor-α, Sterol regulatory element-binding protein",
author = "Oh, {Kyoung Jin} and Jinyoung Park and Lee, {Su Yeon} and Injae Hwang and Kim, {Jae Bum} and Park, {Tae Sik} and Heon-Jeong Lee and Seung-Hoi Koo",
year = "2011",
month = "4",
day = "1",
doi = "10.1152/ajpendo.00502.2010",
language = "English",
volume = "300",
pages = "624--632",
journal = "American Journal of Physiology - Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism

AU - Oh, Kyoung Jin

AU - Park, Jinyoung

AU - Lee, Su Yeon

AU - Hwang, Injae

AU - Kim, Jae Bum

AU - Park, Tae Sik

AU - Lee, Heon-Jeong

AU - Koo, Seung-Hoi

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Dysregulation of lipid metabolism is a key feature of metabolic disorder related to side effects of antipsychotic drugs. Here, we investigated the molecular mechanism by which second-generation atypical antipsychotic drugs (AAPDs) affect hepatic lipid metabolism in liver. AAPDs augmented hepatic lipid accumulation by activating expression of sterol regulatory element-binding protein (SREBP) transcription factors, with subsequent induction of downstream target genes involved in lipid and cholesterol synthesis in hepatocytes. We confirmed the direct involvement of SREBPs on AAPD-induced expression of lipogenic and cholesterogenic genes by utilization of adenovirus for dominant negative SREBP (Ad-SREBP-DN). Interestingly, AAPDs significantly decreased phosphorylation of AMPKα and expression of fatty acid oxidation genes. Treatment of constitutive active AMPK restored AAPD-mediated dysregulation of genes involved in both lipid synthesis and fatty acid oxidation. Moreover, AAPDs decreased transcriptional activity of PPARα, a critical transcriptional regulator for controlling hepatic fatty acid oxidation, via an AMPKdependent manner. Close investigations revealed that mutations at the known p38 MAPK phosphorylation sites (S6/12/21A), but not mutations at the putative AMPKα phosphorylation sites (S167/373/453A), block AAPD-dependent reduction of PPARα transcriptional activity, suggesting that p38 MAPK might be also involved in the regulatory pathway as a downstream effector of AAPDs/AMPK. Taken together, these data suggest that AAPD-stimulated hepatic dysregulation of lipid metabolism could result from the inhibition of AMPK activity, and pharmaceutical means to potentiate AMPK activity would contribute to restore hepatic lipid homeostasis that occurs during AAPD treatment.

AB - Dysregulation of lipid metabolism is a key feature of metabolic disorder related to side effects of antipsychotic drugs. Here, we investigated the molecular mechanism by which second-generation atypical antipsychotic drugs (AAPDs) affect hepatic lipid metabolism in liver. AAPDs augmented hepatic lipid accumulation by activating expression of sterol regulatory element-binding protein (SREBP) transcription factors, with subsequent induction of downstream target genes involved in lipid and cholesterol synthesis in hepatocytes. We confirmed the direct involvement of SREBPs on AAPD-induced expression of lipogenic and cholesterogenic genes by utilization of adenovirus for dominant negative SREBP (Ad-SREBP-DN). Interestingly, AAPDs significantly decreased phosphorylation of AMPKα and expression of fatty acid oxidation genes. Treatment of constitutive active AMPK restored AAPD-mediated dysregulation of genes involved in both lipid synthesis and fatty acid oxidation. Moreover, AAPDs decreased transcriptional activity of PPARα, a critical transcriptional regulator for controlling hepatic fatty acid oxidation, via an AMPKdependent manner. Close investigations revealed that mutations at the known p38 MAPK phosphorylation sites (S6/12/21A), but not mutations at the putative AMPKα phosphorylation sites (S167/373/453A), block AAPD-dependent reduction of PPARα transcriptional activity, suggesting that p38 MAPK might be also involved in the regulatory pathway as a downstream effector of AAPDs/AMPK. Taken together, these data suggest that AAPD-stimulated hepatic dysregulation of lipid metabolism could result from the inhibition of AMPK activity, and pharmaceutical means to potentiate AMPK activity would contribute to restore hepatic lipid homeostasis that occurs during AAPD treatment.

KW - Adenosine 5'-monophosphate-activated protein kinase

KW - Peroxisome proliferator-activated receptor-α

KW - Sterol regulatory element-binding protein

UR - http://www.scopus.com/inward/record.url?scp=79955151848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955151848&partnerID=8YFLogxK

U2 - 10.1152/ajpendo.00502.2010

DO - 10.1152/ajpendo.00502.2010

M3 - Article

C2 - 21224484

AN - SCOPUS:79955151848

VL - 300

SP - 624

EP - 632

JO - American Journal of Physiology - Endocrinology and Metabolism

JF - American Journal of Physiology - Endocrinology and Metabolism

SN - 0193-1849

IS - 4

ER -